15 June 2021 - Eton Pharmaceuticals today announced that the U.S. FDA has approved Rezipres (ephedrine hydrochloride injection) for the treatment of clinically important hypotension occurring in the setting of anaesthesia.

“We are excited to see the approval of Rezipres, which is now our second FDA approved ready-to-use hospital injectable product. We believe ready-to-use injectable products provide a compelling benefit to hospitals and reduce the need for hospitals to rely on unapproved compounded products,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “This innovative sulphite-free formulation has been successfully sold in Europe for years, and we are excited to make it available to U.S. patients shortly.”

Read Eton Pharmaceuticals press release